Ontology highlight
ABSTRACT:
SUBMITTER: Kakadia S
PROVIDER: S-EPMC6200076 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Kakadia Sunilkumar S Yarlagadda Naveen N Awad Ramez R Kundranda Madappa M Niu Jiaxin J Naraev Boris B Mina Lida L Dragovich Tomislav T Gimbel Mark M Mahmoud Fade F
OncoTargets and therapy 20181017
Approximately 50% of melanomas harbor an activating <i>BRAF</i> mutation. Combined BRAF and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib are US Food and Drug Administration (FDA)-approved to treat patients with <i>BRAF</i> <sup>V600</sup>-mutated advanced melanoma. Both genetic and epigenetic alterations play a major role in resistance to BRAF inhibitors by reactivation of the MAPK and/or the PI3K-Akt pathways. The role of BRAF in ...[more]